Company profile
Synovics Pharmaceuticals, Inc.
OTC: SYVC · Healthcare · Biotechnology
#522 of 1,422 Healthcare companies by revenue56th-percentile growth
EA Score
——FH —DQ —GM —SS 53
v0.1 · 5/100 weight · pillars only
↑ 3-yr revenue growth, listing tenure · ↓ growth stability, market scale
Methodology →Revenue TTM
$19.1M
Rev growth YoY (TTM)
-18.5%
Net income (FY)
-$4.0M
Employees
155
as of 2026-08-30
Market cap
$3.0k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$26.0M$26.0M2008
Net income-$4.0M-$4.0M2008
Operating income-$2.5M-$2.5M2008
Total assets$22.3M$22.3M2008
Liabilities$17.3M$17.3M2008
Equity$5.0M$5.0M2008
Revenue trend
FY2001 – FY2008 · USD
FY01
FY02
FY03
FY04
FY05
FY06
FY07
FY08
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Synovics Pharmaceuticals, Inc.’s revenue?
Synovics Pharmaceuticals, Inc. booked $26.0M in FY2008 revenue, growing 11% year over year — about the middle of the pack among Healthcare companies we track, at a -15.4% net margin.
Peers · Healthcare
INNOCAN PHARMA Corp59CCelularity Inc.31DNeurobiological Technologies, Inc.——Biocept, Inc.——RBC Life Sciences, Inc.——Gelesis Holdings, Inc.——Neighbors
Broward →Key facts
CEOChristopher J. Flynn
SectorHealthcare
IndustryBiotechnology
HeadquartersFort Lauderdale, FL
ExchangeOTC: SYVC
Employees155
IPO date2004-03-29
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.